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Adverse Drug Reactions (ADRs) are common and are associated with signiﬁcant risk of morbidity,
mortality and admission to hospital. Deciding if a clinical event is an Adverse Drug Reaction, or not, can
be difﬁcult. The decision is often based on clinical judgment alone, yet studies have shown that decisions
based on clinical judgment often vary greatly between raters.
Therefore a number of decision aids or Algorithms have been developed to try and improve this vari-
ability. Studies have shown that the use of algorithms does improve the between and within rater
agreement signiﬁcantly, and gives a semi-quantitative measure of the likelihood of causality. There are
variations between these algorithms but none of them can in themselves prove or disprove causality.
These algorithms, their beneﬁts and their problems will be discussed in this article.
 2009 Elsevier Ltd. All rights reserved.Educational aims
 To discuss the epidemiology of Adverse Drug Reactions
 To illustrate the merits of Algorithms in decisions on causality
of Adverse Drug Reactions
 To illustrate the problems of algorithms in decisions on
causality of Adverse Drug Reactions
 To show the range of ADR algorithms that have been developed1. Introduction
Adverse Drug Reactions are, according to the World Health
Authority deﬁnition, ‘‘any response to a drug which is noxious and
unintended and which occurs at doses normally used in man for
prophylaxis, diagnosis or therapy of disease or for the modiﬁcation
of physiological function’’.1 As such ADRs encompass side effects
which are ‘‘a dose related and predictable reaction to a drug’’ and
drug allergies.
ADRs account for 2–6% of all hospital admissions in the UK,2
these admissions are almost always medical rather than surgical
and only a minority (9.7%) are due to non-prescribable medicines.3
They are a serious problem in terms of morbidity, mortality and the
cost of patient care. In the USA it has been estimated that up to 20%
of hospitalized patients suffer at least one ADR during an admis-
sion. Also in the United States medication related deaths (excluding
illicit use) account for 120,000 deaths a year,4 another studyAll rights reserved.suggests that about three of every 1000 hospital admissions die as
a result of an ADR.5 The economic impact of ADRs is massive; they
increase hospital stays by almost two days on average, with its
intending costs. The total cost of ADRs in the USA has been esti-
mated to exceed the cost of all diabetes treatment.
2. Recognition of ADRs
The ADRs produced by a certain new drug are often recognized
when the medication is undergoing its phase three randomized
controlled trials. Both in the USA and in the UK there is post
marketing surveillance of ADRs. In the UK this involves reporting
suspected ADRs to the Commission on Human Medicine using the
yellow card system. In this system new or intensively monitored
medicines should have all suspected ADRs reported and other
medicines should have any suspected serious ADR reported. In spite
of these mechanisms ADRs are vastly under reported6 and initial
reports of adverse reactions to drugs have taken up to seven years
for trends to begin to appear in the literature.
Under reporting of ADRs is likely to be due to a number of
reasons. Reporting is notmandatory to clinicians in the UK and so is
likely to be forgotten about amongst the many other work pres-
sures. A clinician may have problems recognizing the scenario as an
ADR, because of the background symptoms of the patient’s original
illness. Clinicians might also be wary of reporting an ADR, because
of worries of inducing a complaint, even in this no blame culture
NHS. It should be pointed out that the yellow card clearly states you
do not need to be sure if it is or is not an ADR before you report it.
In recognizing an ADR there are a number of important factors.
One is identifying those individuals in whom ADRs are most likely
to occur. This includes the aged and the premature, those with liver
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certain individual conditions, such as Human Immunodeﬁciency
Virus infection (HIV).
3. Assessment of causality
It is often difﬁcult to decide if an adverse clinical event is an ADR
or due to deterioration in the primary condition. Furthermore, if it is
an ADR, which medicine caused it, as many patients are on multiple
new medications when ill, particularly if admitted to hospital.
In spite of these problems, the decision that a particular drug
caused an ADR is usually based on clinical judgment alone. Studies
have shown that there is a lot of variation in between rater and
within rater decisions on causality of ADRs; this applies both to
pharmacologists and physicians.7,8 In one study two physicians and
four pharmacists were asked to decide about 63 possible cases, they
showed a between rater agreement of 38% to 63%.9 Another
previously published study showed a 50% agreement between two
raters with a Kw value of 0.3.10 These problems with using indi-
vidual clinical decision making in allotting causality for a change in
clinical condition to a medication led to the development of
a number of decision aids.
4. The beneﬁts of algorithms
Decision aids or algorithms were developed in the 70s and 80s,
they tend to consist of yes/no questions, which can be used to
categorise causality. For instance the Jones’ algorithm11 will cate-
gorise the causality into remote, possible, probable or highly
probable. Other algorithms consist of yes/no questions, the answers
to which correspond to a set score. So by answering all the ques-
tions in the algorithm you end up with a total score, this numerical
score then corresponds to a given category of causality.
There are beneﬁts in the use of such algorithms; including
standardization of methods. Algorithms being structured systems
speciﬁcally designed for the identiﬁcation of an ADR, should
theoretically make a more objective decision on causality. As such
algorithms should have a better between and within rater agree-
ment than clinical judgment. Indeed this has been shown to be the
case.9 In this study the between rater agreement of a panel of
experts, using clinical judgment ranged from 41% to 57%
(kappa¼ 0.21–0.37, R(est)¼ 0.49). When the same individuals used
the Naranjo Algorithm it rose to between 83% and 92%
(kappa¼ 0.69–0.86, r¼ 0.92), this rise being statistically signiﬁcant.
The within rater agreement was also high using the algorithm,
being between 80% and 97% (kappa¼ 0.64–0.95, r¼ 0.95).
5. Comparing the algorithms
A number of algorithms or decision aids have been published
including the Jones’ algorithm,11 the Naranjo algorithm,9 the Yale
algorithm,12 the Karch algorithm,13 the Begaud algorithm,14 the
ADRAC,15 the WHO-UMC16 and a newer quantitative approach
algorithm.17 Each of these algorithms has similarities and differ-
ences. An example of one of the more commonly used algorithms;
the Naranjo algorithm (Fig. 1) is shown below. The consistency of
three of these algorithmswas directly compared in a study in 1986.18
In this study 28ADRswere assessed using the Jones’, the Yale and the
Naranjo algorithms. There was 67% agreement between the Yale and
the Naranjo algorithm (Kw¼ 0.43), similarly there was 67% agree-
ment (Kw¼ 0.48) between the Yale and the Jones’ algorithm.
Agreement between the Naranjo and the Jones’ algorithms was 64%
but the Kw value was only 0.28.These levels of agreement are better
than those that have previously been reportedwhen two raters have
compared the same ADRs using clinical judgment.They concluded that the Naranjo algorithm compared well with
the Yale in scoring ADRs but had the advantage of being less time
consuming. The Yale algorithm containing 57 questions compared
to the 10 questions in the Naranjo algorithm. They were less
supportive of the use of the Jones’ algorithm in view of its lesser
agreement with the Naranjo algorithm. To reduce the ambiguity in
the assessment of potential ADRs these algorithm have been
introduced at pharmacovigilence centres in many countries.
6. Problems with algorithms
Although algorithms have better reproducibility than clinical
judgment in rating ADRs, clinical judgment with its low inter- and
intra-rater agreement still plays a big part in the identiﬁcation and
rating of potential ADRs by an algorithm. This is because the answers
to some of the questions in the algorithmmay be affected by clinical
judgment. More importantly the ﬁrst step in ADR identiﬁcation
depends on a clinical judgment, i.e. the decision that thismight be an
ADR and so deserves further assessment using an algorithm.
Further problems include that the questions in an algorithm are
often weighted, these weights are arbitrarily assigned based on
their perceived importance and vary between algorithms. This
qualitative assigning of weights means that algorithms are unable
to truly determine the probability of the ADR causality.
Even though algorithms have been shown to be more repro-
ducible than clinical judgment alone, the validity of the measure
must also be considered. The fact that the algorithms agree well
with each other does not mean that they are right. Studies have
looked at the validity of algorithms, by comparing the category of
causality that they produce to the decision on causality decided by
a group of experts in the ﬁeld. This is not a true test of the validity of
an assessment system, as this testing cannot work as for as the
majority of ADRs, no true ‘‘Gold Standard’’ exists.
Further problems include the idea that most include questions
on dechallenge/rechallenge, and the rechallenge often does not
occur in the ‘‘real world’’ of clinical practice. This might not occur
for a number of reasons, for many serious ADRs rechallenge might
be considered unethical, since it may pose a considerable risk to the
patient. Also for many lesser potential ADRs using a different drug
rather than undergoing the rechallenge may well be deemed an
easier and simpler option by the clinician. Even if the clinician is
willing to consider rechallenge to strengthen the probability of
causality for an ADR, the patients themselves will often refuse such
a rechallenge. Without a rechallenge it is difﬁcult with most of
these algorithms for causality to be graded more than ‘‘possible’’.
Algorithms depend on a YES/NO answer to individual questions,
this is not always easy, sometimes a ‘‘maybe’’ might be more
appropriate. So in away algorithmsmay simply replace honestywith
pragmatism. Lastly there are a great number of ADRs in a number of
different body systems, so a single standardized assessment tool may
not be ideal for such a diversity of possible presentations.More recent
work has tried to develop assessment schemes for individual prob-
lems e.g. liver disease, interstitial lung disease, and renal failure.19
7. Summary
In summary algorithms are useful in assessing causality in
possible ADRs, as they decrease the disagreement between asses-
sors and can classify uncertainty in a semi-quantitative way. They
are often used by journals and national pharmacovigilence orga-
nizations to mark individual case reports. They improve the
scientiﬁc basis of causality assessment and are useful in education
about causality assessment. However they cannot prove or disprove
causality, nor give an accurate quantitative measurement of the
likelihood of a relationship.
The Naranjo Algorithm is a questionnaire designed by Naranjo et al  for determining the likelihood of 
whether an ADR (adverse drug reaction) is actually due to the drug rather than the result of other factors. 
Probability is assigned via a score termed definite, probable, possible or doubtful. Values obtained from 
the algorithm are sometimes used in peer reviews to verify the validity of author’s conclusions regarding 
adverse drug reactions. It is also called the Naranjo Scale or Naranjo Score.
1) Are there previous conclusive reports of this reaction?
If YES = +1, NO = 0, Do not know or not done = 0
2) Did the adverse event appear after the suspected drug was given?
If YES = +2, NO = -1, Do not know or not done = 0
3) Did the adverse reaction improve when the drug was discontinued or a specific antagonist was 
given?
If YES = +1, NO = 0, Do not know or not done = 0
4) Did the adverse reaction appear when the drug was readministered?
If YES = +2, NO = -2, Do not know or not done = 0
5) Are there alternative causes that could have caused the reaction?
If YES = -1, NO = +2, Do not know or not done = 0
6) Did the reaction reappear when a placebo was given?
If YES = -1, NO = +1, Do not know or not done = 0
7) Was the drug detected in any body fluid in toxic concentrations?
If YES = +1, NO = 0, Do not know or not done = 0
8) Was the reaction more severe when the dose was increased or less severe when the dose was 
decreased?
If YES = +1, NO = 0, Do not know or not done = 0
9) Did the patient have a similar reaction to the same or similar drug drugs in any previous 
exposure?
If YES = +1, NO = 0, Do not know or not done = 0
10) Was the adverse event confirmed by any objective evidence?
If YES = +1, NO = 0, Do not know or not done = 0
SCORING
9 = DEFINITE ADR
5-8 = PROBABLE ADR
1-4 = POSSIBLE ADR
0 = DOUBTFUL ADR
Fig. 1. Naranjo algorithm.
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A 27 year old man presented to hospital with pleuritic chest
pain, shortness of breath and cough. His chest X-ray showed right
basal consolidation, he had a raised CRP and white cell count. His
medication prior to this illness was Olanzapine 15 mg once per day,
which he has taking for a prior diagnosis of schizophrenia, he had
been on this medication for 8 months in all.
He was originally treated as a case of community acquired
pneumonia but on antibiotics his symptoms deteriorated so he
went on to have a C.T. Pulmonary Angiogram, this showed multiple
Pulmonary Emboli. Subsequent investigation showed that he also
had nephrotic syndrome with proteinuria of 2.84 g/l and a serum
albumen of 21 g/l a Kidney biopsy showed he had membranous
glomerulonephritis. Later 24 h urine collection showed a protein-
uria of over 8 g/l.
He was started on diuretics, enalopril and 20 mg of predniso-
lone, this failed to signiﬁcanlty improve his proteinuria. The ques-
tion of if his nephrotic syndrome could be due to his Olanzapine
was then raised and his Olanzapine was stopped.Question 1
Using the Naranjo Algorith how likley is it that the Olanzapine
has caused the nephrotic syndrome?A 29 year old man with severe uncontrolled asthma in spite of
treatment with Uniphyline, montelukast, inhaled corticosteroids
and a long acting beta agonist combination, nebulised bronchodi-
lators and multiple coarses of systemic steroinds was found to have
a raised Ig E level of 343 IU/ml. As he had had several admissions to
hospital with his asthma, he was assessed for treatment with
Omalizumab (an anti Ig E antibody) as per NICE Guidelines. He was
started on Omalizumab 300 mg sub cutaneously each fortnight.
This resulted in improvements in his lung function, symptoms and
quality of life measurements.
Six weeks after starting the Omalizumab he presented to
hospital with crushing central chest pain, which came on after
a weekend absailing, a sport he had never previously been able to
partake in.
Although his e.c.g. was normal, his troponin was raised at 0.23,
a non ST elevation myocardial infarct was diagnosed. He went on to
have coronary angiography with stenting of his LAD. He made
a rapid recovery. At the patients bequest his treatment with
Omalizumabwas continued. Eighteen months latet he continues to
objectively beneﬁt from the Omalizumab and he has had no further
symptoms of Ischaemic Heart Disease.Question 2
Using the Naranjo Algorithm, how likely is it that the Omali-
zumab caused the myocardial infarction?
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respiratory clinic for assessment of his COPD. His past medical
history included Abdominal Aorta Repair, Coronary artery by-pass
operation for Ischemic Heart Disease, Osteoarthritis of both knees
and Dyslipidemia. His medication included Bisoprolol, salbutamol
via a metred dose inhaler as required, Perindopril, Aspirin, Sim-
vastatin and Omeprazole.
On assessment in the clinic he had dyspnoea for 10 years,
with a decreased exercise tolerance and he had a number of
exacerbations in the last year. He was an ex-smoker with
a smoking history of 80 pack years. Spirometry performed in
clinic revealed a forced expiratory volume (FEV1) of 0.97 liters
increasing to 1.1 liters after 400 mcg of Salbutamol. On Spirometry
he had moderate COPD (as per NICE Guidelines) with FEV1 of
42% of predicted and an obstructive pattern with a FEV1/FVC ratio
of 52%.
Hewas started on amaximal inhaled treatment of Salbutamol (2
puffs 4 times a day), Tiotropium -18 mcg once a day, Seretide 500
Accuhaler twice a day (a combination of ﬂuticasone 500 mcg and
Salmeterol 50 mcg). At follow up, he complained that he had had
severe pain in both of his heels over the area of Achilles Tendons
that started two weeks after starting the Seretide. Therefore he
stopped the statin and the inhaled steroid (Seretide) and the
symptoms resolved completely. On reintroduction of inhaled
steroid the symptoms of tendonitis recurred again after twoweeks.
On examination there was some swelling and crepitus felt over the
Achilles Tendons, after which, he was advised to stop Seretide for
the second time, this again resulted in complete resolution of his
symptoms.
Evidence of focal thickening and increased vascularity in the
area of Achilles Tendonswas observed on performing an ultrasound
of his tendons; radiologically conﬁrming the clinical diagnosis of
Achilles tendonitis.Question 3
Using the Naranjo Algorithm how likely is it that the inhaled
corticosteroid caused the tendinitis?Answers
Question 1: Olanzapine and the Nephrotic Syndrome
Total score +2 so a possible ADR.
No previous reports of Olanzapine and the nephrotic
syndrome scores zero, but it did occur after the Olanzapine
so scores +2.
It is not clear if it improves onwithdrawal as this is only occuring
now and no rechallenge has occurred.
No Olanzapine levels reported and no increased doses given, all
score zero.
There are other causes of membranous glomerulonephritis
minus one point.
There is objective evidence scores plus one point.
Question 2: Omalizumab and Myocardial Infarction
Total score zero, therefore doubtful ADR.
Scoring similar to before but, no recurrence on restarting the
Omalizumab post MI scores minus 2, making total score zero.
Question 3: Inhaled Corticosteroids and Achilles Tenosynovitis
Total score probably an eight, therefore probable ADR.
There is subjectivity to the scoring in all cases but this case
clearly scores higher.Are there previous reports, not to inhaled but to other forms of
steroids is this a zero or a + one.
It occured after the drug was given scores plus two.
It went when withdrawn scores plus one.
It came back on rechallenge scores plus two. He had a similar
reaction ﬁrst time he had the drug and there was objective
evidence of the ADR.
The total score is probably arguable but is between 6 and 8.
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online.
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c) Should you successfully complete the test, you may download
your accreditation certiﬁcate (subject to an administrative
charge).Educational questions
Answer true or false to the following statements:
1. With regards to Adverse Drug Reactions (ADRs)
a) These are deﬁned as a dose related and predictable reaction
to a drug
b) These account for 2-6% of all hospital admissions in the UK
c) The majority of admissions due to ADRs are surgical,
particularly peptic ulceration and pancreatitis
d) The total cost of ADRs in the USA has been estimated to
exceed the costs of cardiac treatment
e) When they occur in hospital they tend to increase the
length of stay by an average of almost two days
2. Recognition of Adverse Drug Reactions
a) Occurs predominantly during the phase three randomized
controlled trials
b) Reporting of an ADR is mandatory in the UK
c) Occurs more commonly in the aged and premature
d) Is always easy
e) Reporting of an ADR should occur through the yellow card
system in the USA
3. With regard to dechallenge/rechallenge
a) This should always occur, so as to prove causality
b) Is central to most causality algorithms
c) Is easy to perform
d) Should be performed with the patient blinded to what is
occurring
e) Proves causality in an ADR
4. The problems with Algorithms in assessing ADRs include.
a) Better reproducibility
b) The removal of clinical judgment from the assessment of
causality
c) There is no true gold standard
d) The questions in the algorithms do not always reﬂect real
clinical practice
e) A standardized assessment tool may not be ideal for all
disease processes
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a) Their ease of use
b) Increased between rater agreement
c) Education about causality assessment
d) Proof of causality
e) Classifying uncertainty semi-quantitativelyReferences
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